Found 3 articles
Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics
Big Cypress Acquisition Corp announced that it will hold a Special Meeting of stockholders to, among other matters, allow its stockholders to approve the proposed business combination with SAB Biotherapeutics, Inc..
The business combination agreement will advance SAB’s proprietary platform to develop antibody therapies for immune system disorders and other diseases.
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human Antibody Platform with Demonstrated Utility in Immunotherapy and Rapid Response to Emerging Diseases
SAB Biotherapeutics, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces targeted, high potency, fully-human polyclonal antibodies at scale, and Big Cypress Acquisition Corp., a blank check company focused on innovative biopharmaceutical firms, announced that they have entered into a definitive business combination agreement.